Interaction between cholecystokinin and the fibroblast growth factor system in the ventral tegmental area of selectively bred high- and low-responder rats

Neuroscience

Volumn 255, Issue , 2013, Pages 68-75

  Ballaz, S J ^a   Perez, J ^a   Waselus, M ^a   Akil, H ^a   Watson, S J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Colocalization; Fibroblast growth factor receptor 1; Fibroblast growth factor 2; In situ hybridization; Individual differences; Novelty response

Indexed keywords

CHOLECYSTOKININ; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE EXPRESSION; IN SITU HYBRIDIZATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; VENTRAL TEGMENTUM;

ANALYSIS OF VARIANCE; ANOVA; BHR; BLR; BRED HIGH-RESPONDERS; BRED LOW-RESPONDERS; CCK; CHOLECYSTOKININ; COLOCALIZATION; DIG; DIGOXIGENIN; ELEVATED PLUS-MAZE; EPM; FGF-R1; FGF2; FIBROBLAST GROWTH FACTOR RECEPTOR-1; FIBROBLAST GROWTH FACTOR-2; FIBROBLAST GROWTH FACTOR-2 (BASIC FIBROBLAST GROWTH FACTOR); IN SITU HYBRIDIZATION; INDIVIDUAL DIFFERENCES; INTEGRATED OPTICAL DENSITY; IOD; NOVELTY RESPONSE; ROSTRAL VTA; VENTRAL TEGMENTAL AREA; VTA; VTAR;

ANIMALS; ANXIETY; AUTORADIOGRAPHY; CHOLECYSTOKININ; EXPLORATORY BEHAVIOR; FIBROBLAST GROWTH FACTOR 2; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOTOR ACTIVITY; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER; VENTRAL TEGMENTAL AREA;

EID: 84887159790     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.09.063     Document Type: Article

References (55)

1. Ballaz S., Akil H., Watson S.J. The CCK-system mediates adaptation to novelty-induced stress in the rat: a pharmacological evidence. Neurosci Lett 2007, 428:27-32.
2. Ballaz S., Akil H., Watson S.J. The CCK-system underpins novelty-seeking behavior in the rat: gene expression and pharmacological analysis. Neuropeptides 2008, 42:245-253.
3. Beck K.D. Functions of brain-derived growth factor, insulin-like growth factor-1 and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. Prog Neurobiol 1994, 44:497-516.
4. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., Benoliel J.J. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 2008, 13:1079-1092.
5. Beiderbeck D.I., Reber S.O., Havasi A., Bredewold R., Veenema A.H., Neumann I.D. High and abnormal forms of aggression in rats with extremes in trait anxiety - involvement of the dopamine system in the nucleus accumbens. Psychoneuroendocrinology 2012, 37:1969-1980.
6. Beinfeld M.C. Cholecystokinin in the central nervous system: a minireview. Neuropeptides 1983, 3:411-427.
7. Beinfeld M.C. What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization. Life Sci 2003, 73:643-654.
8. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006, 26:12014-12022.
9. Bertolucci-D'Angio M., Serrano A., Scatton B. Mesocorticolimbic dopaminergic systems and emotional states. J Neurosci Methods 1990, 34:135-142.
10. Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev 2012, 36:79-89.
11. Chen Q., Nakajima A., Meacham C., Tang Y.P. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc Natl Acad Sci USA 2006, 103:3881-3886.
12. Clinton S.M., Turner C.A., Flagel S.B., Simpson D.N., Watson S.J., Akil H. Neonatal fibroblast growth factor treatment enhances cocaine sensitization. Pharmacol Biochem Behav 2012, 103:6-17.
13. Cooper B.R., Breese G.R., Grant L.D., Howard J.L. Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine. J Pharmacol Exp Ther 1973, 185:358-370.
14. Corral-Frias N.S., Lahood R.P., Edelman-Vogelsang K.E., French E.D., Fellous J.M. Involvement of the ventral tegmental area in a rodent model of post-traumatic stress disorder. Neuropsychopharmacology 2013, 38:350-363.
15. Coutts J.C., Gallagher J.T. Receptors for fibroblast growth factors. Immunol Cell Biol 1995, 73:584-589.
16. Crespi F., Corsi M., Regianni A., Ratti E., Gaviraqhi C. Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands. Expert Opin Investig Drugs 2000, 9:2249-2258.
17. Cuevas P., Fernández-Ayerdi A., Carceller F., Colin S., Mascarelli F., Muñoz-Willery I., Giménez-Gallego G. Central nervous system distribution of fibroblast growth factor injected into the blood stream. Neurol Res 1996, 18:267-272.
18. de Oliveira A.R., Reimer A.E., Brandão M.L. Role of dopamine receptors in the ventral tegmental area in conditioned fear. Behav Brain Res 2009, 199:271-277.
19. 125I-labeled basic fibroblast growth factor. Pharm Res 2000, 17:63-69.
20. Flagel S.B., Clark J.J., Robinson T.E., Mayo L., Czuj A., Willuhn I., Akers C.A., Clinton S.M., Phillips P.E., Akil H. A selective role for dopamine in stimulus-reward learning. Nature 2011, 469:53-57.
21. Flores J.A., Galan-Rodriguez B., Rojo A.I., Ramiro-Fuentes S., Cuadrado A., Fernandez-Espejo E. Fibroblast growth factor-1 within the ventral tegmental area participates in motor sensitizing effects of morphine. Neuroscience 2010, 165:198-211.
22. Gelowitz D.L., Kokkinidis L. Enhanced amygdala kindling after electrical stimulation of the ventral tegmental area: implications for fear and anxiety. J Neurosci 1999, 19:RC41.
23. Gonzalez A.M., Berry M., Maher P.A., Logan A., Baird A. A comprehensive analysis of the distribution of FGF2 and FGFR1 in the rat brain. Brain Res 1995, 701:201-226.
24. Graham B.M., Richardson R. Memory of fearful events: the role of fibroblast growth factor-2 in fear acquisition and extinction. Neuroscience 2011, 189:156-169.
25. Guillonneau X., Tassin J., Berrou E., Bryckaert M., Courtois Y., Mascarelli F. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity. J Cell Physiol 1996, 166:170-187.
26. Hansen T.V., Nielsen F.C. Regulation of neuronal cholecystokinin gene transcription. Scand J Clin Lab Invest (Suppl) 2001, 234:61-67.
27. Hansen T.V., Rehfeld J.F., Nielsen F.C. Mitogen-activated protein kinase and protein kinase A signaling pathways stimulate cholecystokinin transcription via activation of cyclic adenosine 3',5'-monophosphate response element-binding protein. Mol Endocrinol 1999, 13:466-475.
28. Harro J. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids 2006, 31:215-230.
29. Harro J., Marcusson J., Oreland L. Alterations in brain cholecystokinin receptors in suicide victims. Eur Neuropsychopharmacol 1992, 2:57-63.
30. Hebb A.L., Zacharko R.M., Dominguez H., Trudel F., Laforest S., Drolet G. Odor-induced variation in anxiety-like behavior in mice is associated with discrete and differential effects on mesocorticolimbic cholecystokinin mRNA expression. Neuropsychopharmacology 2002, 27:744-755.
31. Hökfelt T., Rehfeld J.F., Skirbol L.L., Ivermark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in meso-limbic neurons. Nature 1980, 285:476-478.
32. Hoshi H., Logsdon C.D. Direct trophic effects of fibroblast growth factors on rat pancreatic acinar cells in vitro. Biochem Biophys Res Commun 1993, 196:1202-1207.
33. Kabbaj M., Devine D.P., Savage V.R., Akil H. Neurobiological correlates of individual differences in novelty-seeking behavior in the rat: differential expression of stress-related molecules. J Neurosci 2000, 20:6983-6988.
34. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., Maher P.A., Hard R., Richards J., Stachowiak E.K., Stachowiak M.K. Fibroblast growth factor receptor signalling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J Neurochem 2006, 97:1243-1258.
35. Olson V.G., Nestler E.J. Topographical organization of GABAergic neurons within the ventral tegmental area of the rat. Synapse 2007, 61:87-95.
36. Olson V.G., Zabetian C.P., Bolanos C.A., Edwards S., Barrot M., Eisch A.J., Hughes T., Self D.W., Neve R.L., Nestler E.J. Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci 2005, 25:5553-5562.
37. Panksepp J., Burgdorf J., Beinfeld M.C., Kroes R.A., Moskal J.R. Regional brain cholecystokinin changes as a function of friendly and aggressive social interactions in the rat. Brain Res 2004, 1025:75-84.
38. Paxinos G., Watson C. The rat brain in stereotactic coordinates 2007, Academic Press, London. 6th ed.
39. Perez J., Clinton S.M., Turner C.A., Watson S.J., Akil H. A new role for FGF-2 as an endogenous inhibitor of anxiety. J Neurosci 2009, 29:6379-6387.
40. Piazza P.V., Deminière J.M., Le Moal M., Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989, 245:1511-1513.
41. Pratt J.A., Brett R.R. The benzodiazepine receptor inverse agonist FG 7142 induces cholecystokinin gene expression in rat brain. Neurosci Lett 1995, 184:197-200.
42. Ratineau C., Dreau S., Blanc M., Bernard C., Cordier-Bussat M., Abello J., Chayvialle J., Roche C. CCK expression in enteroendocrine cell is regulated by soluble factor(s) from underlying fibroblasts. Mol Cell Endocrinol 2001, 175:5-13.
43. Ratzka A., Baron O., Stachowiak M.K., Grothe C. Fibroblast growth factor 2 regulates dopaminergic neuron development in vivo. J Neurochem 2012, 122:94-105.
44. Seroogy K.B., Dangaran K., Lim S., Haycock J.W., Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 1989, 279:397-414.
45. Sherrin T., Todorovic C., Zeyda T., Tan C.H., Wong P.T., Zhu Y.Z., Spiess J. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Mol Psychiatry 2009, 14:291-307.
46. Stead J.D., Clinton S., Neal C., Schneider J., Jama A., Miller S., Vazquez D.M., Watson S.J., Akil H. Selective breeding for divergence in novelty-seeking traits: heritability and enrichment in spontaneous anxiety-related behaviours. Behav Genet 2006, 36:697-712.
47. Suzuki K., Okada K., Wakuda T., Shinmura C., Kameno Y., Iwata K., Takahashi T., Suda S., Matsuzaki H., Iwata Y., Hashimoto K., Mori N. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. PLoS One 2010, 5:e9260.
48. Szebenyi G., Fallon J.F. Fibroblast growth factors as multifunctional signalling factors. Int Rev Cytol 1999, 185:45-106.
49. Turner C.A., Flagel S.B., Clinton S.M., Akil H., Watson S.J. Cocaine interacts with the novelty-seeking trait to modulate FGFR1 gene expression in the rat. Neurosci Lett 2008, 446:105-107.
50. Turner C.A., Gula E.L., Taylor L.P., Watson S.J., Akil H. Antidepressant like effects of intracerebroventricular FGF2 in rats. Brain Res 2008, 1224:63-68.
51. Turner C.A., Watson S.J., Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 2012, 76:160-174.
52. van Megen H.J., Westenberg H.G., den Boer J.A., Kahn R.S. Cholecystokinin in anxiety. Eur Neuropsychopharmacol 1996, 6:263-280.
53. Wagner J.P., Black I.B., DiCicco-Bloom E. Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci 1999, 19:6006-6016.
54. Wang H., Zhu Y.Z., Wong P.T., Farook J.M., Teo A.L., Lee L.K., Moochhala S. CDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test. Exp Brain Res 2003, 149:413-421.
55. Zwanzger P., Domschke K., Bradwejn J. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety 2012, 29:762-774.